Skip to main content
Premium Trial:

Request an Annual Quote

DxS and BTG to Market AstraZeneca s DNA Diagnostic Technology

NEW YORK, March 23 (GenomeWeb News) - DxS and BTG said today that they have signed an exclusive license to commercialize technology developed by AstraZeneca for the detection of SNPs and other gene mutations.

DxS and BTG said they had acquired "certain rights" to AstraZeneca's technology, and would market AstraZeneca's Amplification Refractory Mutation System (ARMS) within the diagnostic and research markets.

The technology will be targeted toward companies that offer genetic variation products and services, as well as companies that are already using ARMS as part of their in-house research activities, DxS and BTG said.

DxS, a genetic analysis services provider, will offer ARMS in addition to its own Scorpions genotyping system. Stephen Little, DxS CEO, called ARMS "an excellent fit with our current portfolio."

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more